
Dr Boreham’s Crucible: Telix has homework but remains dux of radioimaging class
Tim Boreham is one of Australia's leading business journalists. Pic: supplied With multiple clinical trials and approval applications in train, nuclear medicine superstar Telix Pharmaceuticals (ASX:TLX) is like one of those irritatingly brilliant all- …